Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ: OBIO )

5.290 +0.140 (+2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance 
From Precision Neuroscience
Via GlobeNewswire
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Strengthens Senior Leadership Team
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.